Reporting LDL cholesterol results by clinical biochemistry laboratories in Czechia and Slovakia to improve the detection rate of familial hypercholesterolemia

Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

(2021) Camilla Ditlev Lindhardt Johannesen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

(2021) Frank L J Visseren et al.   EUROPEAN HEART JOURNAL

SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe

(2021) et al.   EUROPEAN HEART JOURNAL

FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia

(2021) Felix Fath et al.   Scientific Reports

How well do laboratories adhere to recommended guidelines for dyslipidaemia management in Europe? The CArdiac MARker Guideline Uptake in Europe (CAMARGUE) Study

(2020) Hélène A. De Wolf et al.   CLINICA CHIMICA ACTA

Worldwide Prevalence of Familial Hypercholesterolemia

(2020) Sabina O. Beheshti et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol

(2020) Angelos D Karagiannis et al.   EUROPEAN HEART JOURNAL

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

(2019) Richard Ceska et al.   Current Atherosclerosis Reports

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

(2019) Michel R. Langlois et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Standardization of laboratory and lipid profile evaluation: A call for action with a special focus in 2016 ESC/EAS dyslipidaemia guidelines – Full report

(2018) Pedro Marques da Silva et al.   ATHEROSCLEROSIS SUPPLEMENTS

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

(2018) Stephen Burgess et al.   JAMA Cardiology

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

(2018) Antonio J. Vallejo-Vaz et al.   ATHEROSCLEROSIS

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

(2017) Robert P Giugliano et al.   LANCET

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

Lipoprotein (a) measurements for clinical application

(2015) Santica M. Marcovina et al.   JOURNAL OF LIPID RESEARCH

Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group

(2014) Michel R. Langlois et al.   ATHEROSCLEROSIS

Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile

(2013) Seth S. Martin et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: Comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects

(2012) Takashi Miida et al.   ATHEROSCLEROSIS

Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

(2011) Paul N. Hopkins et al.   Journal of Clinical Lipidology